Clinical trial
A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
NCT04052555 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1b Study of Berzosertib in Combination With Radiation Therapy to Overcome Therapeutic Resistance in Chemotherapy Resistant Triple Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- September 24, 2020
- Completion date
- February 24, 2027
- Enrollment
- 42 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
bilateral breast carcinoma, her2-negative breast carcinoma, localized breast carcinoma, recurrent breast carcinoma, triple-negative breast carcinoma